Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir

European Journal of Clinical Pharmacology

Volumn 70, Issue 10, 2014, Pages 1173-1179

  Song, Ivy ^a   Borland, Julie ^a   Chen, Shuguang ^a   Guta, Phyllis ^b   Lou, Yu ^a   Wilfret, David ^a   Wajima, Toshihiro ^c   Savina, Paul ^a   Peppercorn, Amanda ^a   Castellino, Stephen ^a   Wagner, David ^a   Hosking, Louise ^b   Mosteller, Michael ^a   Rubio, Justin P ^b   Piscitelli, Stephen C ^a  

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

^c SHIONOGI AND CO LTD   (Japan)

Author keywords

Dolutegravir; Drug interaction; Efavirenz; Tipranavir

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 3A4; DOLUTEGRAVIR; EFAVIRENZ; GLUCURONOSYLTRANSFERASE 2B7; RITONAVIR PLUS TIPRANAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; DRUG COMBINATION; FUSED HETEROCYCLIC RINGS; INTEGRASE INHIBITOR; PYRIDINE DERIVATIVE; PYRONE DERIVATIVE; RITONAVIR; TIPRANAVIR;

ADULT; ALLELE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN EXPERIMENT; LIVER TOXICITY; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; OPEN STUDY; PHARMACOGENETICS; PHASE 1 CLINICAL TRIAL (TOPIC); PLASMA CONCENTRATION-TIME CURVE; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING; AGED; BIOLOGICAL MODEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; DRUG INTERACTION; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; YOUNG ADULT;

ADULT; AGED; ANTI-HIV AGENTS; AREA UNDER CURVE; BENZOXAZINES; CROSS-OVER STUDIES; DRUG COMBINATIONS; DRUG INTERACTIONS; FEMALE; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INTEGRASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PYRIDINES; PYRONES; RITONAVIR; YOUNG ADULT;

EID: 84919922996     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-014-1732-8     Document Type: Article

References (24)

1. Min S, Song I, Borland J, Chen S, Lou Y, Fujiwara T, Piscitelli SC (2010) Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother 54:254-258
2. Walmsley S, Antela A, Clumeck N et al (2012) Dolutegravir (DTG; S/GSK1349572) + abacavir/lamivudine once daily statistically superior to tenofovir/emtricitabine/efavirenz: 48-week results - SINGLE (ING114467). 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, Abstract H-556b
3. Raffi F, Rachlis A, Stellbrink H-J, SPRING-2 Study Group et al (2013) SPRING-2 study group. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 381:735-743
4. Cahn P, Pozniak AL, Mingrone H, Extended SAILING Study Team et al (2013) Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet 382:700-708
5. Nichols G, Mills A, Grossberg R et al (2012) Antiviral activity of dolutegravir in subjects with failure on an integrase inhibitor-based regimen: week 24 phase 3 results from VIKING-3. J Int AIDS Soc 15(suppl 4):18112
6. Castellino S, Moss L, Wagner D et al (2013) Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor, dolutegravir, in humans. Antimicrob Agents Chemother 57:3536-3546
7. Song I, Min SS, Borland J et al (2011) The effect of lopinavir/ritonavir and darunavir/ritonavir on the HIV integrase inhibitor S/GSK1349572 in healthy participants. J Clin Pharmacol 51:237-242
8. Song I, Borland J, Chen S et al (2011) Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572. Br J Clin Pharmacol 72:103-108
9. Song I, Borland J, Min S et al (2011) Effects of etravirine alone and with ritonavir-boosted protease inhibitors on the pharmacokinetics of dolutegravir. Antimicrob Agents Chemother 55:3517-3521
10. Reese MJ, Savina PM, Generaux GT et al (2013) In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metab Dispos 41:353-361
11. Hop CE, Wang Z, Chen Q, Kei G (1998) Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening. J Pharm Sci 87:901-903
12. Sustiva® (efavirenz). Package insert August 2012. Bristol-Myers Squibb, Princeton
13. Dooley KE, Sayre P, Borland J (2013) Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects. J Acquir Immune Defic Syndr 62:21-27
14. Smith PF, DiCenzo R, Morse GD (2001) Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. Clin Pharmacokinet 40:893-905
15. Tozzi V (2010) Pharmacogenetics of antiretrovirals. Antivir Res 85:190-200
16. Vourvahis M, Dumond J, Patterson K et al (2007) Effects of tipranavir/ritonavir (TPV/r) on the activity of hepatic and intestinal cytochrome P450 3A4/5 and P-glycoprotein (P-gp): implications for drug interactions. 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, Poster 563
17. Leith J, Walmsley C, Katlama K et al (2004) Pharmacokinetics and safety of tipranavir/ritonavir alone or in combination with saquinavir, amprenavir, or lopinavir: interim analysis of BI 118.51. 5th International Workshop on Clinical Pharmacology of HIV Therapy. Rome
18. MacGregor TR, Sabo JP, Norris SH, Johnson P, Galitz L, McCallister S (2004) Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers. HIV Clin Trials 5:371-382
19. Hanley WD, Wenning LA, Moreau A (2009) Effect of tipranavir-ritonavir on pharmacokinetics of raltegravir. Antimicrob Agents Chemother 53:2752-2755
20. Mathias AA, Hinkle J, Shen G et al (2008) Effect of ritonavir-boosted tipranavir or darunavir on the steady-state pharmacokinetics of elvitegravir. J Acquir Immune Defic Syndr 49:156-162
21. Song I, Borland J, Chen S et al (2012) Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir. Antimicrob Agents Chemother 56:1627-1629
22. van Lunzen J, Maggiolo F, Arribas JR et al (2012) Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis 12:111-118
23. Song I, Chen S, Piscitelli S, Min S (2013) Pharmacokinetics (PK) and PK-pharmacodynamic (PD) relationship of dolutegravir (DTG) in integrase inhibitor (INI)-naïve subjects. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Denver, Abstract A-1573
24. Song I, Borland J, Lou Y, Chen S, Patel P, Guta P, Wajima T, Peppercorn A, Piscitelli S (2011) Effects of Enzyme Inducers, Tipranavir and Efavirenz, on the Pharmacokinetics of the Integrase Inhibitor, Dolutegravir (S/GSK1349572). 12th International Workshop on Clinical Pharmacology of HIV Therapy. Miami, Oral